These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 21058409)

  • 21. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
    Pfisterer J; Shannon CM; Baumann K; Rau J; Harter P; Joly F; Sehouli J; Canzler U; Schmalfeldt B; Dean AP; Hein A; Zeimet AG; Hanker LC; Petit T; Marmé F; El-Balat A; Glasspool R; de Gregorio N; Mahner S; Meniawy TM; Park-Simon TW; Mouret-Reynier MA; Costan C; Meier W; Reinthaller A; Goh JC; L'Haridon T; Baron Hay S; Kommoss S; du Bois A; Kurtz JE;
    Lancet Oncol; 2020 May; 21(5):699-709. PubMed ID: 32305099
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours.
    Bozionelou V; Vamvakas L; Pappas P; Agelaki S; Androulakis N; Kalykaki A; Nikolaidou M; Kentepozidis N; Giassas S; Marselos M; Georgoulias V; Mavroudis D
    Br J Cancer; 2007 Jul; 97(1):43-9. PubMed ID: 17551496
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II study of neoadjuvant gemcitabine, pegylated liposomal doxorubicin, and docetaxel in locally advanced breast cancer.
    Artioli G; Mocellin S; Borgato L; Cappetta A; Bozza F; Zavagno G; Zovato S; Marchet A; Pastorelli D
    Anticancer Res; 2010 Sep; 30(9):3817-21. PubMed ID: 20944176
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study.
    Asnacios A; Fartoux L; Romano O; Tesmoingt C; Louafi S S; Mansoubakht T; Artru P; Poynard T; Rosmorduc O; Hebbar M; Taieb J
    Cancer; 2008 Jun; 112(12):2733-9. PubMed ID: 18412149
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib.
    El Dika I; Capanu M; Chou JF; Harding JJ; Ly M; Hrabovsky AD; Do RKG; Shia J; Millang B; Ma J; O'Reilly EM; Abou-Alfa GK
    Cancer Med; 2020 Oct; 9(20):7453-7459. PubMed ID: 32841541
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I/II study of gemcitabine with pegylated liposomal doxorubicin as first-line therapy in Asian women with metastatic breast cancer.
    Wong ZW; Ang PC; Chowbay B; Wong NS; See HT; Khoo KS
    Breast; 2008 Oct; 17(5):517-22. PubMed ID: 18502128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single-Agent versus Combination Doxorubicin-Based Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Single-Blind, Randomized, Phase II Trial.
    Liu B; Huang JW; Li Y; Hu BS; He X; Zhao W; Zheng YB; Lu LG
    Oncology; 2015; 89(1):23-30. PubMed ID: 25613214
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum-taxane therapy: a phase II Austrian AGO study.
    Petru E; Angleitner-Boubenizek L; Reinthaller A; Deibl M; Zeimet AG; Volgger B; Stempfl A; Marth C
    Gynecol Oncol; 2006 Aug; 102(2):226-9. PubMed ID: 16443259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer.
    Nakanishi T; Aoki D; Watanabe Y; Ando Y; Tomotsugu N; Sato Y; Saito T
    Jpn J Clin Oncol; 2015 May; 45(5):422-6. PubMed ID: 25670764
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A dose escalation study of pegylated liposomal Doxorubicin (caelyx) in combination with capecitabine (xeloda) in patients with refractory solid tumors.
    Maltezos E; Amarantidis K; Trichas M; Vasiliadis M; Toromanidou M; Chatzaki E; Karayiannakis A; Tsaroucha A; Romanidis K; Kakolyris S
    Oncology; 2005; 69(6):463-9. PubMed ID: 16374040
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: a multicenter, open-label, single-arm phase II study.
    Srimuninnimit V; Sriuranpong V; Suwanvecho S
    Asia Pac J Clin Oncol; 2014 Sep; 10(3):255-60. PubMed ID: 24810940
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study.
    Louafi S; Boige V; Ducreux M; Bonyhay L; Mansourbakht T; de Baere T; Asnacios A; Hannoun L; Poynard T; Taïeb J
    Cancer; 2007 Apr; 109(7):1384-90. PubMed ID: 17330837
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gemcitabine plus doxorubicin as first-line treatment in advanced or metastatic breast cancer (MBC), a phase II study.
    El Serafi MM; El Khodary AI; El Zawahry HR; Mansour OM; Gaballa HE
    J Egypt Natl Canc Inst; 2006 Sep; 18(3):209-15. PubMed ID: 17671530
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Efficacy of Low-Dose Paclitaxel Added to Combination Chemotherapy of Carboplatin and Gemcitabine or Pegylated Liposomal Doxorubicin.
    Nagao S; Iwasa N; Kurosaki A; Nishikawa T; Hanaoka T; Hasegawa K; Fujiwara K
    Int J Gynecol Cancer; 2016 Mar; 26(3):443-8. PubMed ID: 26807640
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma.
    Lind PA; Naucler G; Holm A; Gubanski M; Svensson C
    Acta Oncol; 2007; 46(2):230-3. PubMed ID: 17453374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pegylated liposomal doxorubicin combined with trabectedin as a treatment option in uterine sarcomas: a single-institution retrospective analysis.
    Steinlechner M; Strobel L; Leitner K; Pan TL; Feroz B; Marth C; Zeimet AG
    Int J Gynecol Cancer; 2024 Aug; 34(8):1196-1202. PubMed ID: 38688662
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A clinical trial with valproic acid and hydralazine in combination with gemcitabine and cisplatin followed by doxorubicin and dacarbazine for advanced hepatocellular carcinoma.
    Liu YC; Su CW; Ko PS; Lee RC; Liu CJ; Huang YH; Gau JP; Liu JH
    Asia Pac J Clin Oncol; 2022 Feb; 18(1):19-27. PubMed ID: 32964588
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer.
    D'Agostino G; Ferrandina G; Ludovisi M; Testa A; Lorusso D; Gbaguidi N; Breda E; Mancuso S; Scambia G
    Br J Cancer; 2003 Oct; 89(7):1180-4. PubMed ID: 14520442
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies.
    Fracasso PM; Blum KA; Tan BR; Fears CL; Bartlett NL; Arquette MA; Clark RS
    Cancer; 2002 Nov; 95(10):2223-9. PubMed ID: 12412177
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer.
    Rivera E; Valero V; Syrewicz L; Rahman Z; Esteva FJ; Theriault RL; Rosales MM; Booser D; Murray JL; Bast RC; Hortobagyi GN
    J Clin Oncol; 2001 Mar; 19(6):1716-22. PubMed ID: 11251001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.